The role of monoclonal antibodies in the treatment of lymphomas

Expert Opinion on Biological Therapy

Volumn 13, Issue 2, 2013, Pages 227-239

  Hsu, Jack W ^a   Dang, Nam H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

alemtuzumab; brentuximab; ibritumomab; lymphoma; monoclonal antibodies; ofatumumab; rituximab; therapy; tositumomab

Indexed keywords

ALEMTUZUMAB; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; EPRATUZUMAB Y 90; FIRTECAN; FLUDARABINE; GALIXIMAB; IBRITUMOMAB TIUXETAN; INOTUZUMAB OZOGAMICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; OFATUMUMAB; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; DNA DAMAGE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PERIPHERAL T CELL LYMPHOMA; RADIOIMMUNOTHERAPY; TUMOR CELL DESTRUCTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; LYMPHOMA;

EID: 84872188280     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.755172     Document Type: Article

References (97)

1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975 - 2009 (Vintage 2009
2. Populations). National Cancer Institute, Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975-2009-pops09/; based on November 2011 SEER data submission, posted to the SEER web site, 2012
3. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a Standard Regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6 (Pubitemid 23095683)
4. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54
5. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203-12
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42 .This trial led to R-CHOP becoming the standard of care in the treatment patients > 60 years with newly diagnosed DLBCL. (Pubitemid 34438862)
7. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-44
8. Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47:107-14
9. Davis TA, White CA, Grillo-Lopez AJ, et al. Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-7 (Pubitemid 29269257)
10. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43
11. Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphoma: results of a phase II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000;79:493-50
12. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PRC monitoring of molecular response. Br J Haematol 2000;109:81-8 (Pubitemid 30340582)
13. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-94
14. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade of follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-61 (Pubitemid 29342370)
15. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33 (Pubitemid 28363048)
16. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide and mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed or refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German Low-Grade lymphoma Study Group (GLSG). Blood 2004;104:3064-71 (Pubitemid 39517009)
17. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared to therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32 (Pubitemid 41742196)
18. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23 (Pubitemid 40223656)
19. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-92 (Pubitemid 46972781)
20. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-31
21. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23:1103-8 (Pubitemid 46202265)
22. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416-23 (Pubitemid 38745964)
23. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-94
24. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-Agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28:4480-4
25. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-8 (Pubitemid 44920177)
26. Hochster H, Weller E, Gascoyne RD, et al. Maintenance Rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-14
27. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51
28. van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-301 (Pubitemid 44794222)
29. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-8
30. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91 This trial confirmed R-CHOP as standard of care in patients < 60 years with newly diagnosed DLBCL.
31. Huang BT, Zeng QC, Yu J, et al. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. J Cancer Res Clin Oncol 2012;138:125-32
32. Habermann TM, Weller EA, Morrision VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7 (Pubitemid 46638950)
33. Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-24 (Pubitemid 30056420)
34. Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000;11(Suppl 1):123-6
35. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-92 (Pubitemid 46211378)
36. Kenkre VP, Long WL, Eickhoff JC, et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term followup of a pilot study from the Wisconsin oncology network. Leuk Lymphoma 2011;52:1675-80
37. Ahmadi T, McQuade J, Porter D, et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant 2012;47:1082-6
38. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367:520-31
39. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74
40. Robak T, Dmoszynsks A, Solal-Celigny P. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival compared with fuldarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-64
41. Hale G, Xia M-Q, Tighe HP, et al. The CAMPATH-1H antigen (CDw52). Tissue Antigens 1990;35:118-27
42. Ginaldi L, De martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H. Leuk Res 1998;22:185-91 (Pubitemid 28185349)
43. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61 This trial led to the approval of alemtuzumab in patients with CLL who failed fludarabine-based therapy. (Pubitemid 34534522)
44. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-23 .. This trial led to the approval of alemtuzumab in patients with previously untreated CLL.
45. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011;12:1204-13
46. Stilgenbauer S, Dohner H. CAMPATH-1H-induced complete remission of chronic lymphocytic leukemia despite p53 mutation and resistance to chemotherapy. N Engl J Med 2002;347:452-3 (Pubitemid 34851846)
47. Pettitt AR, Jackson R, Carruthers S, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL206 trial. J Clin Oncol 2012;30:1647-54
48. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010;28:3525-30
49. Teeling JL, Mackus WJM, Wiegman LJJM, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71 (Pubitemid 43939148)
50. Pawluczkowysz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement -dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDDC are induced by OFA than by RTX. J Immunol 2009;183:749-58
51. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-Agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-54 . This trial led to the approval of ofatumumab in the treatment of refractory CLL.
52. Wierda WG, Kipps TJ, Durig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011;117:6450-8
53. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111:5486-94
54. Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012;119:3698-704
55. Coiffer B, Bosly A, Wu KL, et al. Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multicenter phase II study. Blood 2010;116:3955a
56. Czuczman MS, Hess G, Gadeberg OV, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol 2012;157:438-44
57. Matasar MJ, Czuczman MS, Rodriguez MA, et al. A phase II study of ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory aggressive B-cell lymphoma prior to autologous stem cell transplantation (ASCT). Blood 2011;118:957a
58. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007;44:1331-41 (Pubitemid 44415959)
59. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-51 (Pubitemid 46224011)
60. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006;24:3880-6 (Pubitemid 46630735)
61. Micallef INM, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011;118:4053-61
62. Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010;28:3709-16
63. Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther 2011;11:224-34
64. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001;2:203-9 (Pubitemid 33705995)
65. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999;11:203-10 (Pubitemid 29164035)
66. Bhat S, Czuczman MS. Galiximab: a review. Expert Opin Biol Ther 2010;10:451-8
67. Leonard JP, Friedberg JW, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23 (Pubitemid 47244369)
68. Czuczman MS, Leonard JP, Jung S, et al. Phase II trial of galiximab (anti- CD80 monoclonal antibody) plus rituximab (CALGB 50402): follicular lymphoma international prognostic index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol 2012;23:2356-62
69. Smith SM. Galiximab in relapsed Hodgkin lymphoma. Clin Adv Hematol Oncol 2010;8:669-70
70. Olejniczak SH, Steward CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 2006;35:93-114
71. DiJoseph JF, Dougher MM, Evans DY, et al. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol 2011;67:741-9
72. Advani A, Coiffer B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinically activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085-93
73. Goy A, Leach J, Ehmann WC, et al. Inotuzumab ozogamicin (CMC-544) in patients with indolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy or radioimmunotherapy: preliminary safety and efficacy from a phase 2 trial. Blood 2010;116:430a
74. Hatake K, Ogura M, Ando K, et al. Phase 1 study of anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) plus rituximab in Japanese patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. Blood 2010;116:2872a
75. Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprised of two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase 1/2 study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2012; In press
76. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36
77. Fanale M, Forer-Torrez A, Rosenblatt JE, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18:248-54
78. Younes A, Bartlet NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
79. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9 . This trial led to the approval of BV in patients with previously treated HL.
80. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6 This trial led to the approval of BV in patients with previously treated anaplastic large cell lymphoma.
81. Younes A, Connors JM, Park SI, et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. Blood 2011;118:955a
82. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immumol Today 1994;15:450-4 (Pubitemid 24272191)
83. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336-42 (Pubitemid 34627198)
84. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non- Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63 .. This trial led to the approval of 90Y in patients with refractory indolent lymphoma. (Pubitemid 34525730)
85. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004;103:4429-31 (Pubitemid 38745967)
86. Link BK, Martin P, Kaminski MS, et al. Cyclophosphamide, vincristine, and prednisone followed by tosibumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010;28:3035-41
87. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-9 (Pubitemid 46622291)
88. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-704
89. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-64
90. Hagenbeek A, Ralford J, Van Hoof A, et al. 90Y-ibritumomab tiuxetan (Zevalin) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: updated results after a median follow-up of 66.2 months from the international randomized phase III first-line indolent trial (FIT) in 414 patients. Blood 2010;116:594a
91. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28 . This trial led to the approval of 131I in patients with previously treated FL. (Pubitemid 32912019)
92. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1469-79 (Pubitemid 41103630)
93. Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009;9:223-8
94. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lance Oncol 2008;9:352-8
95. Jacobs AS, Swerdlow SH, Kant J, et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:7088-94
96. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lyumphomes de l'Adulte. J Clin Oncol 2005;23:4117-26 (Pubitemid 46211317)
97. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphoma: a randomized controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16